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ABSTRACT
Background Fibroblast to myoﬁbroblast transition is
believed to contribute to airway remodelling in lung
diseases such as asthma and chronic obstructive
pulmonary disease. This study examines the role of
aclidinium, a new long-acting muscarinic antagonist, on
human ﬁbroblast to myoﬁbroblast transition.
Methods Human bronchial ﬁbroblasts were stimulated
with carbachol (10
8 to 10
5 M) or transforming growth
factor-b1 (TGF-b1; 2 ng/ml) in the presence or absence
of aclidinium (10
9 to 10
7 M) or different drug
modulators for 48 h. Characterisation of myoﬁbroblasts
was performed by analysis of collagen type I and
a-smooth muscle actin (a-SMA) mRNA and protein
expression as well as a-SMA microﬁlament
immunoﬂuorescence. ERK1/2 phosphorylation, RhoA-GTP
and muscarinic receptors (M) 1, 2 and 3 protein
expression were determined by western blot analysis
and adenosine 39-59 cyclic monophosphate levels were
determined by ELISA. Proliferation and migration of
ﬁbroblasts were also assessed.
Results Collagen type I and a-SMA mRNA and protein
expression, as well as percentage a-SMA microﬁlament-
positive cells, were upregulated in a similar way by
carbachol and TGF-b1, and aclidinium reversed these
effects. Carbachol-induced myoﬁbroblast transition was
mediated by an increase in ERK1/2 phosphorylation,
RhoA-GTP activation and cyclic monophosphate
downregulation as well as by the autocrine TGF-b1
release, which were effectively reduced by aclidinium.
TGF-b1 activated the non-neuronal cholinergic system.
Suppression of M1, M2 or M3 partially prevented
carbachol- and TGF-b1-induced myoﬁbroblast transition.
Aclidinium dose-dependently reduced ﬁbroblast
proliferation and migration.
Conclusion Aclidinium inhibits human lung ﬁbroblast to
myoﬁbrobast transition.
INTRODUCTION
Remodelling is a pathological feature observed in
the airways of patients with asthma and chronic
obstructive pulmonary disease (COPD), and the
extent and progression of these structural alter-
ations correlate with disease severity.
1 2 Fibrotic
alterations as part of these structural changes are
also observed in both asthma and COPD, although
their nature, localisation and extent are different.
Under chronic inﬂammatory conditions, resident
lung ﬁbroblasts are activated and transformed into
a more contractile, proliferative and secretory-
active myoﬁbroblast phenotype characterised by an
increased expression of extracellular matrix
components and a-smooth muscle actin (a-SMA),
which contribute to the increase in lung remodel-
ling progression and airway bronchoconstrictor
responsiveness.
3
Parasympathetic activity is increased in airway
inﬂammation, which is the basis for the use of
anticholinergic therapy in asthma and COPD.
4
Anticholinergics constitute a particularly impor-
tant bronchodilator therapy in COPD and certain
forms of asthma.
5 Furthermore, anticholinergics
have shown potential anti-inﬂammatory and anti-
remodelling effects in animal models,
6 which may
be of added value to their classical bronchodilator
effects. Recent evidence indicates that acetylcholine
production in the airways is not restricted to the
parasympathetic nervous system but can also be
released from non-neuronal origins.
7 Dysfunction
of the non-neuronal cholinergic system appears to
be involved in the pathophysiology of asthma and
COPD.
8 In this regard, it has been suggested that
ﬁbroblasts are endowed with this system and could
represent a previously unappreciated regulatory
pathway in pulmonary remodelling.
9 Muscarinic
receptor stimulation has been shown to induce
profound proliferation and collagen secretion of
human lung ﬁbroblasts.
10 11 However, the role of
the cholinergic system in ﬁbroblast to myoﬁbro-
blast transition, as well as the mechanisms that
underlie ﬁbroblast activation, remain unclear.
Key messages
What is the key question?
< Does aclidinium, an anticholinergic agent, affect
human ﬁbroblast to myoﬁbroblast transition?
What is the bottom line?
< Aclidinium dose-dependently inhibits human
lung ﬁbroblast to myoﬁbroblast transition
induced by carbachol and TGF-b1 stimulation.
Why read on?
< This is the ﬁrst report of the mechanistic and
functional involvement of a non-neuronal cholin-
ergic system in the transition of human lung
ﬁbroblasts to myoﬁbroblasts. We provide
evidence that the use of anticholinergic agents
such as aclidinium for the treatment of lung
disease may play a role in regulatory ﬁbrotic
remodelling.
< Additional material is
published online only. To view
this ﬁle please visit the journal
online (http://thorax.bmj.com/
content/67/3.toc).
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Chronic obstructive pulmonary diseaseAclidinium bromide (Almirall, Barcelona, Spain) is a novel
long-acting muscarinic antagonist that has reached phase III
clinical development for COPD treatment.
12 In preclinical
studies, aclidinium demonstrated potent muscarinic antagonist
activity comparable to ipratropium and tiotropium, with a long
duration of action.
13 The aim of the present study was to
investigate the effect of aclidinium on regulating carbachol-
induced human lung ﬁbroblast to myoﬁbroblast transition as
well as the mechanism involved in this process. In addition,
since transforming growth factor-b1 (TGF-b1) is the main
known factor responsible for myoﬁbroblast formation and
progression,
14 we examined the effects of aclidinium on TGF-b1-
induced ﬁbroblast to myoﬁbroblast transition and the possible
link between cholinergic and TGF-b1 pathways.
METHODS
Isolation and cultivation of human ﬁbroblasts
Human lung ﬁbroblasts were dissected from lobar or main
bronchus tissue obtained from patients undergoing surgery for
lung carcinoma, as previously described.
10 Data presented
throughout the study were from human bronchial ﬁbroblasts
obtained from patients who smoked. For comparison, bronchial
ﬁbroblasts were also isolated from patients with COPD and only
used to explore the effect of aclidinium on carbachol- or TGF-b1-
induced myoﬁbroblast markers. Cultivation and characterisation
of ﬁbroblasts were performed as described elsewhere
10 11 (for
details and clinical data of patients see online supplement).
Stimulation of human ﬁbroblasts
Before stimulation, subconﬂuent cell monolayers were deprived
of serum for 24 h. Human bronchial ﬁbroblasts were stimulated
with carbachol (Sigma, Madrid, Spain: catalogue no. C4382) or
human TGF-b1 (2 ng/ml; Sigma: catalogue no. T7039) for the
indicated times, replacing culture medium and stimulus every
24 h. Aclidinium, human acetylcholinesterase (10 U/ml; AChE;
Sigma: catalogue no. C1682), dibutyryl adenosine 39-59 cyclic
monophosphate sodium salt (1 mM; dbcAMP; Sigma: catalogue
no. D0260), PD98050 (10 mM; Sigma: catalogue no. P215),
Y27632 (10 mM; Sigma: catalogue no. Y0503), pirenzepine
(described as M1 antagonist, 1 mM; Sigma: catalogue no. P7412),
methoctramine (described as M2 antagonist, 1 mM; Sigma:
catalogue no. M105) and p-ﬂuoro-hexahydro siladifenidol
(pFHHSid) (described as M3 antagonist, 1 mM; Sigma: catalogue
no. H127) were added 30 min before stimulus. Monoclonal anti-
human TGF-b1 monoclonal antibody (4 mg/ml; anti-TGF-b1;
R&D Systems, Madrid, Spain; catalogue no. AB-246-NA) was
added 30 min before stimulus to block the culture supernatant
active form of TGF-b1, as previously outlined.
15
Real-time RT-PCR
Total RNA isolation and speciﬁc cDNA ampliﬁcation for
muscarinic acetylcholine receptors M1, M2, M3, a1(I)-collagen
(col type I), a-SMA and TGF-b1 were referenced to glyceralde-
hyde phosphate dehydrogenase as an endogenous control and
normalised to the control group, as previously described
16 17 (see
online supplement for details).
Transfection of siRNAs
Small interfering RNA (siRNA) experiments for M1, M2 and M3
were performed in lung ﬁbroblasts as previously outlined
16 17
using lipofectamine-2000 (Invitrogen, Paisley, UK) 2 ml/ml as
transfection reagent (see online supplement for details).
Western blotting
Western blot analysis was used to detect changes in col type I
(138 kD), a-SMA, TGF-b1 (4060 kD), p-ERK1/2 (4244 kD),
RhoA-GTP (22 kD), M1 (52 kD), M2 (70 kD), M3 (75 kD) and
choline acetyltransferase (ChAT; 65 kD) (see online supplement
for details).
Immunoﬂuorescence
Fibroblasts were ﬁxed, permeabilised and immunostained with
anti-a-SMA (1:200) antibody, followed by secondary anti-FITC,
as previously outlined
17 (see online supplement for details).
Enzyme-linked immunosorbent assays
Quantitative ELISAs for TGF-b1 and acetylcholine (ACh) were
performed with supernatants of subconﬂuent human lung
ﬁbroblasts on a six-well plate following 48 h of stimulation with
Quantikine human TGF-b1 immunoassay (R&D Systems;
catalogue no. 891124) and ACh assay kit (Abcam, UK; catalogue
no. ab65345), respectively.
The cell content of cAMP was measured as previously
described.
18 Cells were placed in Dulbecco’s modiﬁed Eagle
medium with 1% fetal calf serum (FCS) for 24 h before
measurements to arrest growth. The experimental protocol
Figure 1 Carbachol (CCh) time- and dose-dependently increases collagen type I (col type I) and a-smooth muscle actin (a-SMA) in human lung
ﬁbroblasts. Human lung ﬁbroblasts were stimulated with CCh at the indicated times (A, B) or for 48 h at the indicated concentrations (C, D). (AD)
After incubation, RNA was extracted and subjected to RT-PCR with col type I and a-SMA-speciﬁc primers and probes. (C, D) After incubation, total
protein was extracted and western blot analysis was performed with speciﬁc antibodies for col type I and a-SMA. Each graph represents the mean of
four individual experiments. One-way repeated measures analysis of variance (ANOVA): p<0.001 (AD). *p<0.05 compared with solvent controls.
230 Thorax 2012;67:229e237. doi:10.1136/thoraxjnl-2011-200376
Chronic obstructive pulmonary diseaseconsisted of incubation of cells with aclidinium for 30 min
followed by addition of carbachol (10
5 M) for 10 min and
isoprenaline (10
6 M) for another 10 min. These concentrations
and times of incubation were selected from the literature.
19
Total cAMP content was determined using a commercially
available biotrack enzyme immunoassay kit (reference
RPN2251; Amersham, Bucks, UK) (see online supplement for
details).
Cell proliferation assay and cell migration
Human bronchial ﬁbroblast proliferation and migration
were measured by colorimetric immunoassay based on BrdU
incorporation and wound closure assay, as previously outlined
20
(for details see online supplement).
Analysis of results
Results are expressed as mean (SEM). Comparisons over time or
across different stimulations on matched ﬁbroblast samples of
one subject for n independent subjects were analysed by one-
way repeated measures analysis of variance (ANOVA) with 95%
CIs. For separate comparisons of each stimulation, post hoc
Bonferroni-Holm tests were performed. A p value <0.05 was
considered statistically signiﬁcant.
Figure 2 Carbachol (CCh) and transforming growth factor b1 (TGF-b1)-induced collagen type I (col type I) and a-smooth muscle actin (a-SMA)
expression is inhibited by aclidinium (ACL). Human lung ﬁbroblasts from smokers (black bars) or patients with chronic obstructive pulmonary disease
(COPD) (white bars) were stimulated with CCh (A, B) or TGF-b1 (C, D) for 48 h. Aclidinium was added to the medium at the indicated concentrations
30 min before CCh (A, B) or TGF-b1 stimulation (C, D). Total protein and RNA were extracted after the incubation period. The top graphs represent
values of densitometry of col type I (A, C) or a-SMA (B, D) protein expression relative to b-actin and normalised to solvent controls. Representative
western blots of col type I (A, C) or a-SMA (B, D) are shown. The bottom graphs show RT-PCR for col type I (A, C) or a-SMA (B, D). (E, F) Fibroblasts
were seeded into 12-well plates, each containing a glass coverslip and incubated with CCh (E) or TGF-b1 (F) in the presence or absence of aclidinium.
Cells were then ﬁxed, permeabilised and immunostained with anti-a-SMA followed by secondary anti-FITC. Fluorescence images are representative of
three independent experiments per condition at 3400 and 31000 magniﬁcation. Each graph represents the mean of three experiments for western
blots and eight experiments for RNA experiments. One-way repeated measures analysis of variance (ANOVA): p<0.001 (AD). Post hoc Bonferroni-
Holm tests: *p<0.05 compared with solvent controls; #p<0.05 compared with stimulus.
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Chronic obstructive pulmonary diseaseRESULTS
Aclidinium inhibits carbachol- and TGF-b1-induced collagen type
I and a-SMA expression in human lung ﬁbroblasts
Carbachol (10
5 M) augmented collagen type I and a-SMA
mRNA expression, reaching peak values at 48 h after carbachol
exposure (ﬁgure 1A,B). Furthermore, carbachol dose-dependently
increased collagen type I and a-SMA protein and mRNA
expression reaching signiﬁcant values at 10
5 M( ﬁgure 1C,D).
We therefore selected this carbachol concentration for the rest of
the experiments.
Aclidinium dose-dependently reduced carbachol-induced
collagen type I and a-SMA protein and mRNA expression,
reaching a maximal inhibitory value at 10
7 M( ﬁgure 2A,B; black
bars) in bronchial ﬁbroblasts from smokers. In other experiments,
TGF-b1 caused a pronounced increase in collagen type I and
a-SMA protein and mRNA expression which was almost
completely blocked by aclidinium 10
7 M( ﬁgure 2C,D; black
bars) in bronchial ﬁbroblasts from smokers. For comparison,
bronchial ﬁbroblasts from patients with COPD were stimulated
with carbachol or TGF-b1, reaching slightly higher levels
of collagen type I and a-SMA mRNA transcripts than
those observed in ﬁbroblasts from smokers (ﬁgure 2AeD; white
bars). Aclidinium dose-dependently reduced carbachol- and
TGF-b1-induced collagen type I and a-SMA mRNA in a similar
fashion to that in ﬁbroblasts from smokers (ﬁgure 2AeD;
white bars).
Immunoﬂuorescence of a-SMA in response to carbachol
showed a distinct appearance of numerous bundles of actin
microﬁlaments comparable to the response with TGF-b1
(ﬁgure 2E,F). Control ﬁbroblasts showed diffuse irregular cyto-
plasmic a-SMA staining with no ﬁlamentous pattern. The
percentage of cells expressing a-SMA microﬁlaments following
carbachol or TGF-b1 exposure was 36 (5)% and 60 (10)%,
respectively. Aclidinium 10
7 M signiﬁcantly reduced carbachol-
and TGF-b1-induced a-SMA microﬁlament formation to 5 (2)%
and 15 (3)%, respectively.
Figure 3 Carbachol (CCh)-induced
expression of collagen type I (col type I)
and a-smooth muscle actin (a-SMA) is
partially mediated by transforming
growth factor-b1 (TGF-b1). Human lung
ﬁbroblasts were stimulated with CCh for
48 h. (A, B) Aclidinium (ACL), Rho
kinase inhibitor (Y27632), dibutyryl
cyclic AMP analogue (dbcAMP), ERK1/
2 inhibitor (PD98059), anti-TGF-b1
antibody (4 mg/ml) or their IgG isotypes
were added to the medium 30 min
before CCh stimulation. After
incubation, total protein was extracted
and western blots were performed for
col type I (A) and a-SMA (B). Graphs
from (A) and (B) represent values of
densitometry of col type I (A) and
a-SMA (B) protein expression relative
to b-actin and normalised to solvent
controls. Representative western blots
show col type I (A) and a-SMA (B)
protein expression. In other
experiments, cells were stimulated with
CCh in the presence or absence of ACL
(C, E, F), Y27632 (D, E, F), PD98059 (D,
E, F) or dbcAMP (D, E, F). After
incubation, total protein (C, D), RNA (E)
or cell culture supernatants were
collected and TGF-b1 protein (C, D),
mRNA (E) as well as the active form of
TGF-b1 present in the culture medium
(F) were quantiﬁed by western blot, RT-
PCR and ELISA, respectively. Each
graph represents the mean of three
(AD) or six (E, F) experiments. One-
way repeated measures analysis of
variance (ANOVA): p<0.001 (AF).
Post hoc Bonferroni-Holm tests:
*p<0.05 compared with solvent
controls; #p<0.05 compared with
stimulus.
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Chronic obstructive pulmonary diseaseCarbachol increases myoﬁbroblast markers by a TGF-b1
common mechanism
Carbachol-induced collagen type I and a-SMA protein expres-
sion was suppressed when cells were pretreated with aclidinium,
the Rho kinase inhibitor Y27632, the cAMPanalogue dbcAMPor
the ERK1/2 inhibitor PD98059 (ﬁgure 3A,B). Western blot
analysis showed that carbachol-induced collagen type I and
a-SMA expression was almost completely suppressed by an anti-
TGF-b1 antibody (4 mg/ml) (ﬁgure 3A,B). Furthermore, carba-
chol increased TGF-b1 cellular protein and mRNA expression
(ﬁgure 3CeE) and increased a small but signiﬁcant amount of
extracellular TGF-b1( ﬁgure 3F). Pretreatment of cells with
aclidinium or with Y27632, dbcAMP or PD98059 effectively
suppressed TGF-b1 protein and mRNA expression as well as
TGF-b1 extracellular secretion, even below control levels.
We next explored whether TGF-b1 activates the non-neuronal
cholinergic system. The enzyme AChE (10 U/ml) was used to
remove any extracellular ACh during the 48-hour period of TGF-
b1 stimulation. AChE reduced the increase in collagen type I and
a-SMA expression induced by TGF-b1( ﬁgure 4A,B). However,
the analysis of ACh supernatant levels revealed no differences
between the control group and cells treated with TGF-b1o r
aclidinium (ﬁgure 4C), probably due to the rapid ACh degrada-
tion by extracellular cholinesterases present on ﬁbroblasts.
21 22
In other experiments we observed that TGF-b1 is able to upre-
gulate ChATexpression in human lung ﬁbroblasts and that this
effect is reversed by aclidinium (ﬁgure 4D). All these results
suggest that muscarinic receptor activation may share common
downstream pathways with TGF-b1. This hypothesis is
supported by the inhibition of both carbachol- and TGF-b1-
induced increases in ERK1/2 phosphorylation and RhoA-GTP
formation by aclidinium (ﬁgure 5A,B). Aclidinium also
prevented the inhibition of isoprenaline-induced intracellular
cAMP levels by carbachol (ﬁgure 5C).
Carbachol and TGF-b1 modify muscarinic receptor expression
Human lung ﬁbroblasts showed high levels of mRNA for M2
transcripts and, to a lesser extent, for M1 and M3 transcripts,
respectively (datanotshown),whileM4andM5transcripts were
not detected, consistent with previous reports in primary human
lung ﬁbroblasts.
10 Setting the protein expression level of M1 at 1,
the amount of M2 protein expression in human lung ﬁbroblasts
under basal conditions was approximately 2.6-fold and 2.4-fold
higher than that of M1 and M3, respectively (ﬁgure 6AC).
When cells were incubated with TGF-b1or carbachol for 48 h,
protein expression of M1 and M3 receptors was upregulated
while M2 expression was downregulated (ﬁgure 6A,B). Aclidi-
nium pretreatment prevented the upregulation of M1 and M3,
but not M2 downregulation induced by carbachol or TGF-b1
(ﬁgure 6A,B). In parallel experiments, Y27632, dbcAMP or
PD98059reducedthecarbachol-inducedM1andM3upregulation
but did not modify M2 expression (ﬁgure 6C).
To better understand which muscarinic receptor is involved in
myoﬁbroblast transition, ﬁbroblasts were preincubated with the
Figure 4 Transforming growth factor-
b1 (TGF-b1)-induced expression of
collagen type I (col type I) and
a-smooth muscle actin (a-SMA) is
partially mediated by the non-neuronal
acetylcholine system. Human lung
ﬁbroblasts were stimulated with
TGF-b1 for 48 h. (A, B) Acetyl
cholinesterase was added to the
medium 30 min before TGF-b1
stimulation. After incubation, total
protein was extracted and western
blots were performed for col type I and
a-SMA. The graphs in (A) and (B)
represent values of densitometry of col
type I and a-SMA protein expression
relative to b-actin and normalised to
solvent controls, respectively.
Representative western blots show col
type I (A) and a-SMA (B) protein
expression. In other experiments (C, D),
cells were stimulated with TGF-b1 for
48 h in the presence or absence of
aclidinium (ACL). After incubation, cell
culture supernatants (C) and total
protein (D) were collected.
Acetylcholine (ACh) supernatant levels
were measured by ELISA (C), and
choline acetyltransferase (ChAT)
expression (D) was quantiﬁed by
western blot analysis, related to b-actin
and normalised to solvent controls.
Each graph represents the mean of
three (AD) individual experiments.
One-way repeated measures analysis of
variance (ANOVA): p<0.001 (AD).
Post hoc Bonferroni-Holm tests: *p<0.05
compared with solvent controls; #p<0.05 compared with stimulus.
Thorax 2012;67:229e237. doi:10.1136/thoraxjnl-2011-200376 233
Chronic obstructive pulmonary diseaseM1 antagonist pirenzepine, M2 antagonist methoctramine or
M3 antagonist pFHHSid. Both collagen type I and a-SMA
expression increased by carbachol or TGF-b1 were prevented by
M1, M2 and M3 antagonists, although the M2 antagonist
methoctramine was less effective at inhibiting a-SMA expres-
sion (ﬁgure 6D,E). In other experiments in which M1, M2 and
M3 receptors were selectively silenced by transfecting cells with
siRNA-M1, siRNA-M2 and siRNA-M3, carbachol-induced
collagen type I and a-SMA were totally suppressed (ﬁgure 6F).
Aclidinium inhibits common phenotypic alterations of
myoﬁbroblasts
Subconﬂuent cells were exposed to TGF-b1 or carbachol for 48 h
in the presence or absence of aclidinium (10
9 to 10
7 M).
Both TGF-b1 and carbachol increased cell proliferation by
approximately 2.25- and 1.75-fold, respectively (ﬁgure 7AC).
Aclidinium dose-dependently inhibited the TGF-b1 and carba-
chol-induced cell proliferation with statistical signiﬁcance at
10
8 M and 10
7 M( ﬁgure 7A,B). Furthermore, Y27632,
dbcAMP and PD98059 preincubation effectively reduced cell
proliferation induced by carbachol (ﬁgure 7C). In other experi-
ments, human bronchial ﬁbroblast closure studies were
performed to analyse cell migration. Aclidinium (ﬁgure 7D,E)
and Y27632, dbcAMP and PD98059 (ﬁgure 7F) dose-dependently
inhibited cell migration and wound closure.
DISCUSSION
This study describes for the ﬁrst time the mechanistic and
functional involvement of a non-neuronal cholinergic system in
the lung ﬁbroblast to myoﬁbroblast transition and provides
evidence for the use of anticholinergic agents in lung diseases in
which lung remodelling occurs. The relevance of these ﬁndings
was highlighted by the ﬁnding that aclidinium effectively
attenuated carbachol- and TGF-b1-induced myoﬁbroblast tran-
sition in bronchial ﬁbroblasts from smokers and patients with
COPD. These observations suggest that aclidinium may have
anti-remodelling properties in addition to its sustained bron-
chodilation and positive safety proﬁle for anticholinergic adverse
events observed in clinical trials.
23
Myoﬁbroblasts are characterised by secretion of extracellular
matrix components such as collagen type I (a characteristic
shared with ﬁbroblasts) and by formation of contractile appa-
ratus such as a-SMA microﬁlaments (a characteristic shared
with airway smooth muscle cells). Furthermore, myoﬁbroblasts
show a high proliferative and migratory activity under inﬂam-
matory conditions.
3 In this respect, recent human in vivo
evidence has shown that muscarinic agonist (methacholine)
inhalation promotes myoﬁbroblast expansion and airway
smooth muscle dedifferentiation into myoﬁbroblasts that
migrate to the submucosal level.
24 These data, together with the
capacity of ACh to promote ﬁbroblast proliferation and collagen
secretion, suggest that the cholinergic system may be involved
in the process of ﬁbroblast to myoﬁbroblast transition and
contribute to the increased pool of myoﬁbroblasts that has been
observed in the lungs of patients with asthma and COPD.
Until now, available data of muscarinic agonist effects on lung
ﬁbroblasts have been restricted to ﬁbroblast proliferation and
collagen synthesis.
10 11 25 In this study we show for the ﬁrst
time that collagen type I and a-SMA microﬁlaments are upre-
gulated following carbachol exposure. Furthermore, we demon-
strate a link between the cholinergic and TGF-b1 systems.
Previous reports showed that cholinergic receptor stimulation
may increase the expression and release of TGF-b in different cell
types.
26e28 Recently it was observed that lung ﬁbroblasts
stimulated with interleukin 1b (IL-1b), tumour necrosis factor
a (TNFa) or cigarette smoke extract increase ChAT expression,
suggesting the presence of a non-neuronal ACh system in lung
ﬁbroblasts.
9 In our study, carbachol increased TGF-b1 expression
and secretion, which may account for the induction of collagen
type I and a-SMA which was inhibited by an anti-TGF-b1
antibody. Furthermore, aclidinium was able to signiﬁcantly
reduce the TGF-b1 expression and secretion induced by carba-
chol, which indicates that muscarinic receptors are also involved
in this process. Similar to what occurs under inﬂammatory
conditions, TGF-b1 was able to increase ChAT expression and,
more interestingly, the addition of AChE suppressed the TGF-
b1-induced increase in collagen type I and a-SMA. These results
suggest that TGF-b1 activates a non-neuronal cholinergic
system.
Since carbachol and TGF-b1 may alter cell markers to induce
ﬁbroblast to myoﬁbroblast transition, changes in the expression
of M receptors may also be expected. The pattern of M receptor
expression on lung ﬁbroblasts has recently been studied in
Figure 5 Carbachol (CCh)-induced ERK1/2 phosphorylation, RhoA-GTP
expression and cAMP inhibition are prevented by aclidinium (ACL).
Human lung ﬁbroblasts were stimulated with CCh or transforming
growth factor-b1 (TGF-b1) for 48 h (A, B). ACL was added to the
medium 30 min before CCh or TGF-b1 stimulation (A, B). After
incubation, total protein was extracted and western blots for pERK1/2,
total ERK1/2 (A) and RhoA-GTP, RhoA (B) were performed. (C) ACL was
incubated for 30 min followed by the addition of CCh for 10 min and
isoprenaline (ISO) (10
6 M) for another 10 min. Total cAMP content was
determined using biotrack enzyme immunoassay kit and absorbance
was read at 450 nm. The Western blots (A, B) are representative of
three independent experiments. (C) represents the mean of three
individual experiments. One-way repeated measures analysis of variance
(ANOVA): p<0.001 (C). Post hoc Bonferroni-Holm tests: *p<0.05
compared with solvent controls; #p<0.05 compared with ISO;
Ap<0.05 related to CCh plus ISO.
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29 but data on the expression of myoﬁbroblast M receptors
are scarce. It has been reported that human lung ﬁbroblasts
express high amounts of M2 mRNA transcripts and protein
followed by M1 and, to a lesser extent, M3,
92 9which is in
agreement with our results (ﬁgure 6). Interestingly, both carba-
chol and TGF-b1 increased M1 and M3 protein expression and
reduced M2 expression after 48 h of exposure. Similar ﬁndings
were also shown in lung ﬁbroblasts following exposure to IL-1b,
TNFa or cigarette smoke extract.
9 Furthermore, lung ﬁbroblasts
from patients with COPD showed an upregulation of M1 and
M3 and downregulation of M2 with respect to control subjects.
9
Previous reports also showed that TGF-b1 downregulates M2
expression in human embryonic lung ﬁbroblasts
30 and may
increase M3 expression in smooth muscle cells.
31 Since the
myoﬁbroblast phenotype possesses morphological and
biochemical features intermediate between ﬁbroblasts and
smooth muscle cells, the M1 and M3 upregulation found after
myoﬁbroblast transition could be related to their high contrac-
tile cellular capacity, as shown previously.
32 These results are
consistent with the in vivo conditions where M3 and, to a lesser
extent, M1 are coupled to Gq protein and therefore contribute to
bronchial and tracheal smooth muscle contraction.
8 We also
found that the antimuscarinic aclidinium attenuates M1 and
M3 upregulation induced by carbachol and TGF-b1, which in
turn correlates with the inhibitory effect of aclidinium on
ﬁbroblast to myoﬁbroblast transition.
It remains unclear whether there is a speciﬁc muscarinic
receptor involved in ﬁbroblast to myoﬁbroblast transition. Until
now, M2 was considered to be the main receptor subtype
responsible for ﬁbroblast proliferation and collagen synthesis.
These data were based on the high M2 expression and by
the action of the Gi/o protein inhibitor pertussis toxin and
M-subtype antagonists with a limited selective action.
10 11
Results from lung ﬁbroblasts recently showed that all musca-
rinic receptors are involved in ﬁbroblast proliferation.
9 In the
present study we further evaluate this thesis by using pharma-
cological intervention (M1, M2 and M3 antagonists) as well as
genetic techniques that allow speciﬁc silencing of each receptor
(siRNAs of M1, M2 and M3). We demonstrated that collagen
type I and a-SMA upregulationdand therefore myoﬁbroblast
transitiondis mediated by these three types of muscarinic
receptors.
Figure 6 Carbachol (CCh) and transforming growth factor b1 (TGF-b1) alter muscarinic receptor (M) expression and induce ﬁbroblast to myoﬁbroblast
transition via M1, M2 and M3. Human lung ﬁbroblasts were stimulated with TGF-b1 (A) or CCh (B, C) for 48 h. (A, B) aclidinium (ACL), (C) Rho kinase
inhibitor (Y27632), (C) dibutyryl cyclic AMP analogue (dbcAMP) or ERK1/2 inhibitor (PD98059) were added to the medium 30 min before stimulation.
After incubation, total protein was extracted and western blots were performed for M1, M2 and M3. The graphs (A, B, C) represent values of
densitometry of M1, M2 or M3 protein expression relative to b-actin and normalised to solvent controls; representative western blots are also shown
for M1, M2 and M3. In other experiments, cells were stimulated with TGF-b1 (D) or CCh (E) in the presence or absence of M1 antagonist pirenzepine,
M2 antagonist methoctramine or M3 antagonist p-ﬂuoro-hexahydro siladifenidol (pFHHSid) for 48 h. After incubation, total protein was extracted and
western blots were performed for collagen type I (col type I) and a-smooth muscle actin (a-SMA). The graphs (D, E) represent values of densitometry of
col type I and a-SMA protein expression relative to b-actin and normalised to solvent controls; representative western blots are shown for col type I
and a-SMA. (F) Left black graphs show M1, M2 and M3 mRNA expression after 48 h of treatment with siRNA-M1, M2 and M3. Right graph (F) shows
cells selectively transfected with siRNA-M1, M2 and M3 that were stimulated with CCh for 48 h. After incubation, total protein was extracted and col
type I and a-SMA protein expression were expressed relative to b-actin and normalised to solvent controls. Representative western blots are shown for
col type I and a-SMA. Each graph represents the mean of three (AF) individual experiments. One-way repeated measures analysis of variance
(ANOVA): p<0.001 (AF). Post hoc Bonferroni-Holm tests: *p<0.05 compared with solvent controls; #p<0.05 compared with stimulus.
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Chronic obstructive pulmonary diseaseThere is also evidence of ERK1/2 involvement on the
muscarinic agonist-induced ﬁbroblast proliferation and collagen
synthesis.
9 10 25 In the present study we found that carbachol
and TGF-b1 induce ERK1/2 phosphorylation, and that this
effect was effectively blocked by aclidinium. Furthermore,
PD98059, the speciﬁc inhibitor of ERK1/2, attenuates carbachol-
induced collagen type I and a-SMA upregulation, cell prolifera-
tion and migration, as well as TGF-b1 expression and secretion.
Similar results were observed for RhoA activation and cAMP
downregulation induced by carbachol. It is known that musca-
rinic receptors and TGF-b1 activate ERK1/2 and RhoA-GTP.
82 8
RhoA activation has been implicated in ﬁbroblast proliferation
and migration,
33 and increased intracellular cAMP levels act as
a potent inhibitor of the ﬁbroblast to myoﬁbroblast transition.
34
In this study, aclidinium was shown to inhibit RhoA-GTP
formation and prevent carbachol-induced cAMP down-
regulation. Interestingly, the inhibitors of Rho kinase (Y27632
and dbcAMP) were able to inhibit ﬁbroblast to myoﬁbroblast
transition as well as cell proliferation and migration. These data
support ERK1/2, RhoA-GTP and cAMP as intracellular messen-
gers that contribute to carbachol-induced ﬁbroblast to myoﬁ-
broblast transition (ﬁgure 8). Furthermore, the muscarinic
antagonist aclidinium inhibits the activation of ERK1/2 and
RhoA-GTP by carbachol and TGF-b1, and prevents the decrease
of cAMP levels, which in turn inhibits the myoﬁbroblast tran-
sition (ﬁgure 8).
In addition to the pathways explored in this work, numerous
previous studies have shown that TGF-b1 induces myoﬁbroblast
differentiation including collagen and a-SMA expression via
Smad-mediated pathways. It has recently been shown that the
anticholinergic tiotropium may suppress TGF-b1-induced
Smad2/4 activation in lung ﬁbroblasts suggesting a crosstalk
between TGF-b1 and muscarinic signalling.
35
Figure 7 Aclidinium inhibits ﬁbroblast
proliferation and migration.
Semiconﬂuent ﬁbroblasts were grown
in 96-well plates in the presence or
absence of transforming growth factor
b1 (TGF-b1) (A) or carbachol (CCh) (B)
for 48 h. (A, B) Aclidinium (ACL), (C)
Rho kinase inhibitor (Y27632), dibutyryl
cyclic AMP analogue (dbcAMP) or
ERK1/2 inhibitor (PD98059) were added
to the medium 30 min before
stimulation. After incubation, cell
proliferation was assessed by
colorimetric BrDU assay. In panels
(DF), ﬁbroblasts were stimulated for
48 h with CCh or vehicle (control) in the
presence or absence of ACL (D, E),
Y27632 (F), dbcAMP (F) or PD98059
(F). After stimulation, a circular wound
edge was created in the centre of the
well by removing a p-200 pipette tip.
The cells were washed and re-exposed
to the same conditions and wound
closure was monitored for 24 h and
48 h. (D) Circular wound closure image
at 350 ﬁnal augmentation (scale bar
60 mm). Each graph represents the
mean of three individual experiments.
One-way repeated measures analysis of
variance (ANOVA): p<0.001 (AF).
Post hoc Bonferroni-Holm tests: *p<0.05
compared with solvent controls; #p<0.05 compared with stimulus.
Figure 8 Model to explain the transforming growth factor b1 (TGF-b1)-
induced non-neuronal cholinergic system on bronchial ﬁbroblast to
myoﬁbroblast transition as well as the inhibitory effect of aclidinium
(ACL). The muscarinic receptor agonist carbachol (CCh) increases the
myoﬁbroblast markers collagen type I (Col type I) and a smooth muscle
actin (a-SMA) through the phosphorylation of extracellular signal-
regulated protein kinase (ERK)-1/2 and activation of Rho kinase. Depletion
of intracellular cyclic AMP (cAMP) induced by CCh also contributes to Col
type I and a-SMA upregulation. CCh activates the expression and
secretion of TGF-b1 which activates the choline acetyltransferase (ChAT)
expression and activity in an autocrine fashion. ChAT increases the
synthesis and secretion of acetylcholine (ACh) which activates the
muscarinic receptors and promotes ﬁbroblast to myoﬁbroblast transition
in an autocrine fashion. The antimuscarinic aclidinium (ACL) inhibits the
effects of CCh and ACh on ﬁbroblast to myoﬁbroblast transition. Thus,
ACL inhibits ERK1/2 phosphorylation, Rho kinase activation, cAMP
downregulation and Col type I and a-SMA expression. Furthermore, ACL
inhibits TGF-b1 expression and secretion as well as the non-neuronal
cholinergic activation of ﬁbroblast to myoﬁbroblast transition.
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Chronic obstructive pulmonary diseaseIn summary, we have shown that activation of muscarinic
receptors induces ﬁbroblast to myoﬁbroblast transition through
an increase in ERK1/2 phosphorylation, RhoA-GTP formation
and downregulation of cAMP levels and provide evidence that
cholinergic and TGF-b1 pathways interact to induce myoﬁbro-
blast transition. The muscarinic antagonist aclidinium was
a potent inhibitor of the ﬁbroblast to myoﬁbroblast transition
following carbachol or TGF-b1 exposure. We therefore conclude
that, in addition to its bronchodilatory activity, aclidinium
may play a role in regulating ﬁbrotic remodelling in chronic
inﬂammatory diseases such as asthma and COPD.
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